ArticlePLoS biology2022
Longitudinal deep sequencing informs vector selection and future deployment strategies for transmissible vaccines.
Article in PLoS biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Evaluating vectors for the design of a spillover-disrupting Lassa virus transmissible vaccine.PLoS computational biology · 2026Article
- Virus-Dependent Geographic Structure of Co-Circulating Viruses in a Single Bat Species.Molecular ecology · 2026Article
- Bat things come in threes: within-host dynamics of herpesvirus triple infection in bats.Journal of virology · 2025Article
- Role of individual and population heterogeneity in shaping dynamics of multi-pathogen shedding in an island endemic bat.PLoS pathogens · 2025Article
- Design of field trials for the evaluation of transmissible vaccines in animal populations.PLoS computational biology · 2025Article
- Demographic and zoological drivers of infectome diversity in companion cats with ascites.mSystems · 2024Article
- Interferons and tuft cell numbers are bottlenecks for persistent murine norovirus infection.PLoS pathogens · 2024Article
- Developing transmissible vaccines for animal infections.Science (New York, N.Y.) · 2024Article
- Inferring the disruption of rabies circulation in vampire bat populations using a betaherpesvirus-vectored transmissible vaccine.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Effects of culling vampire bats on the spatial spread and spillover of rabies virus.Science advances · 2023Article
- Quantifying Spillover Risk with an Integrated Bat-Rabies Dynamic Modeling Framework.Transboundary and emerging diseases · 2023Article
- Ecological determinants of rabies virus dynamics in vampire bats and spillover to livestock.Proceedings. Biological sciences · 2022Article
- One step closer to a transmissible vaccine for rabies virus.PLoS biology · 2022Article
- Recombinant transmissible vaccines will be intrinsically contained despite the ability to superinfect.Expert review of vaccinesArticle
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Vaccination is a powerful tool in combating infectious diseases of humans and companion animals. In most wildlife, including reservoirs of emerging human diseases, achieving sufficient vaccine coverage to mitigate disease burdens remains logistically unattainable. Virally vectored "transmissible" vaccines that deliberately spread among hosts are a potentially transformative, but still theoretical, solution to the challenge of immunising inaccessible wildlife. Progress towards real-world application is frustrated by the absence of frameworks to guide vector selection and vaccine deployment prior to major in vitro and in vivo investments in vaccine engineering and testing. Here, we performed deep sequencing on field-collected samples of Desmodus rotundus betaherpesvirus (DrBHV), a candidate vector for a transmissible vaccine targeting vampire bat-transmitted rabies. We discovered 11 strains of DrBHV that varied in prevalence and geographic distribution across Peru. The phylogeographic structure of DrBHV strains was predictable from both host genetics and landscape topology, informing long-term DrBHV-vectored vaccine deployment strategies and identifying geographic areas for field trials where vaccine spread would be naturally contained. Multistrain infections were observed in 79% of infected bats. Resampling of marked individuals over 4 years showed within-host persistence kinetics characteristic of latency and reactivation, properties that might boost individual immunity and lead to sporadic vaccine transmission over the lifetime of the host. Further, strain acquisitions by already infected individuals implied that preexisting immunity and strain competition are unlikely to inhibit vaccine spread. Our results support the development of a transmissible vaccine targeting a major source of human and animal rabies in Latin America and show how genomics can enlighten vector selection and deployment strategies for transmissible vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.